MA33351B1 - Stable form n (2.6 dimethyl 4-morpholine 4-phenyl) - Google Patents

Stable form n (2.6 dimethyl 4-morpholine 4-phenyl)

Info

Publication number
MA33351B1
MA33351B1 MA34435A MA34435A MA33351B1 MA 33351 B1 MA33351 B1 MA 33351B1 MA 34435 A MA34435 A MA 34435A MA 34435 A MA34435 A MA 34435A MA 33351 B1 MA33351 B1 MA 33351B1
Authority
MA
Morocco
Prior art keywords
dimethyl
morpholine
phenyl
stable form
dimethylbutyramide
Prior art date
Application number
MA34435A
Other languages
Arabic (ar)
French (fr)
Inventor
Svend Treppendahl
Karin Liltorp
De Diego Heidi Lopez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33351(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA33351B1 publication Critical patent/MA33351B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)

Abstract

L'invention porte sur des formes polymorphes du N-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide ainsi qu'un procédé pour la fabrication dudit composé.The invention provides polymorphic forms of N- (2,6-dimethyl-4-morpholin-4-ylphenyl) -3,3-dimethylbutyramide and a process for the manufacture of said compound.

MA34435A 2009-05-11 2010-05-11 Stable form n (2.6 dimethyl 4-morpholine 4-phenyl) MA33351B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11
PCT/DK2010/050101 WO2010130260A2 (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide

Publications (1)

Publication Number Publication Date
MA33351B1 true MA33351B1 (en) 2012-06-01

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34435A MA33351B1 (en) 2009-05-11 2010-05-11 Stable form n (2.6 dimethyl 4-morpholine 4-phenyl)

Country Status (23)

Country Link
EP (1) EP2430008A2 (en)
JP (1) JP2012526152A (en)
KR (1) KR20120022934A (en)
CN (1) CN102459208A (en)
AR (1) AR076556A1 (en)
AU (1) AU2010246724B2 (en)
BR (1) BRPI1013930A2 (en)
CA (1) CA2761383A1 (en)
CL (1) CL2011002814A1 (en)
CO (1) CO6460741A2 (en)
CR (1) CR20110590A (en)
DO (1) DOP2011000351A (en)
EA (1) EA201171381A1 (en)
GE (1) GEP20146006B (en)
IL (1) IL216148A0 (en)
MA (1) MA33351B1 (en)
MX (1) MX2011011885A (en)
NZ (1) NZ596738A (en)
SG (1) SG175968A1 (en)
TN (1) TN2011000557A1 (en)
TW (1) TW201041857A (en)
WO (1) WO2010130260A2 (en)
ZA (1) ZA201108112B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
BRPI0716715B1 (en) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc 4-(N-AZACICLOALKYL) DERIVATIVES AS POTASSIUM CHANNEL MODULATORS, THEIR USES, PRODUCT, COMPOSITION, TABLET AND CAPSULE
CN101790374A (en) * 2007-08-01 2010-07-28 H.隆德贝克有限公司 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Also Published As

Publication number Publication date
AR076556A1 (en) 2011-06-22
IL216148A0 (en) 2012-01-31
SG175968A1 (en) 2011-12-29
NZ596738A (en) 2013-04-26
AU2010246724B2 (en) 2013-03-21
AU2010246724A1 (en) 2011-12-08
JP2012526152A (en) 2012-10-25
CN102459208A (en) 2012-05-16
CO6460741A2 (en) 2012-06-15
KR20120022934A (en) 2012-03-12
TW201041857A (en) 2010-12-01
EP2430008A2 (en) 2012-03-21
GEP20146006B (en) 2014-01-10
WO2010130260A2 (en) 2010-11-18
ZA201108112B (en) 2013-01-30
TN2011000557A1 (en) 2013-05-24
WO2010130260A9 (en) 2012-10-18
WO2010130260A3 (en) 2011-06-16
EA201171381A1 (en) 2012-05-30
CL2011002814A1 (en) 2012-04-13
DOP2011000351A (en) 2012-01-31
MX2011011885A (en) 2011-12-06
CR20110590A (en) 2012-02-22
CA2761383A1 (en) 2010-11-18
BRPI1013930A2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
BRPI0519726A2 (en) (r) -8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride crystalline forms
TW200738688A (en) Compounds for the treatment of inflammatory disorders
DK2824183T3 (en) Process for the production of bispecific antibodies
EA200800549A1 (en) REGIONAL SELECTIVE METHOD FOR OBTAINING BENZIMIDAZOLTHIOPHENES
GT200500296A (en) ASYMMETRIC SYNTHESIS OF DEHYDROBENZOFURAN DERIVATIVES
MA32977B1 (en) Polymorphic of (s) -3-aminomethyl-7-(3-hydroxy-propoxy) -3h-benzo (c (1,2) oxporol-1-ol
BRPI1010128A2 (en) "Process for the manufacture of 2,3,3,3 - tetrafluropropene"
PL380915A1 (en) Method for the manufacture of the nitride semiconductor base as well as nitride semiconductor base
IT1392456B1 (en) PROCESS FOR THE SYNTHESIS OF L-PHUCOSILATED OLIGOSACCHARIDES AND THEIR NEW INTERMEDIATES 2,3,4-TRIBENZYL-FUCHOSIL-DERIVATIVES.
BRPI0710199A2 (en) HIV PROTEASE PREPARATION PROCESS
DK2082054T3 (en) Process for improving the yield of cellulose conversion processes
MX2009000480A (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents.
TW200728310A (en) Process for the preparation of ferri-succinylcasein
NO20071254L (en) Process for the preparation of irbesartan and its intermediates.
EA200870038A1 (en) METHOD OF OBTAINING AMINES
BRPI0914400A2 (en) "process for the synthesis of a compound"
MY148880A (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
FI20050736A (en) Quality of real-time service
FR2950880B1 (en) PROCESS FOR THE PREPARATION OF ANHYDRITE FOR THE MANUFACTURE OF A MORTAR
HN2009001437A (en) NEW PROCEDURE FOR OBTAINING THE CRYSTAL FORM V OF THE AGOMELATINE
MA29092B1 (en) PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED SALICYLAMIDES
MA33351B1 (en) Stable form n (2.6 dimethyl 4-morpholine 4-phenyl)
ATE486049T1 (en) GUIDING DEVICE FOR THE NECK RING OF A GLASSWARE PRODUCING MACHINE
ZA201001694B (en) Process for the manufacture of bridged monobactam intermediates
GB0713566D0 (en) The Synthesis of,N-alkylbis(orciny)phenox AZinones;N-alkyl 3,6-D1(1'3'-Dihydroxy-5'-methylbenzene 6')4,5-Dimethylphenoxazin-2-one-7-oxides